Discover how researchers are looking beyond individual neurons to understand how genetic variations shape activity across ...

Explore how dual binding assays reveal interactions between bispecific antibodies and their targets, providing insights into ...

The critical question they all should be asking is, “How can AI advance our drug development strategy?” rather than, “What’s ...

Advances in biolayer interferometry enable the analysis of small molecule interactions, providing new insights into binding kinetics and affinity.

The first proof-of-concept study showed that the gene therapy reduced the production of cerebrospinal fluid in the brains of ...

Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

On the one hand, lab technology has seen tremendous advancements in the past 50 years. The instruments are more sophisticated than ever and are powered by informatics solutions that enable scientists ...

Until recently, the rare genetic disease, aromatic L-amino acid decarboxylase (AADC) deficiency, had no cure. The disease, which begins in the first months after birth, affects physical, mental, and ...

As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

Antibody-drug conjugates are deceptively simple in concept: an antibody selectively delivers a cytotoxic payload to cancer cells. Manufacturing them at scale is anything but simple. ADC production ...

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...